# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sugar Ray Robinson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX003-SYN-TD
- Date: 1984-08-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Langston Pryce-Okonjo, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six-week review: amyloid PET result and the diagnosis. **S**

## History of present illness

Sugar Ray Robinson returns six weeks after intake with his care partner, whom he asked to be present. The amyloid PET two weeks ago was positive. He was asked first how much he wanted to know and said he wanted it straight. The diagnosis of Alzheimer's disease at the stage of mild dementia was explained with the PET, MRI and test results, in plain words and in writing. He was quiet, then asked whether boxing had caused it; that question was answered honestly. His home glucose readings ran 95 to 150 mg/dL, with one reading of 68 mg/dL before lunch on glipizide. He has not driven. His care partner finds the evenings and the repeated questions tiring. **S**

| Element | Detail |
|---|---|
| Amyloid PET | Positive, widespread cortical uptake |
| Diagnosis | Mild dementia due to Alzheimer's disease, early onset |
| Home glucose | 95 to 150 mg/dL; one reading of 68 mg/dL on glipizide |
| ECG | Sinus rhythm 70, normal intervals |
| Care partner | Zarit Burden Interview 18 (mild), narrative |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Neurological | Positive | Memory loss unchanged; no falls |
| Psychiatric | Negative | Sad at the news but not depressed; no thoughts of self-harm |
| Endocrine | Positive | One low glucose reading before lunch, with sweating |

3 systems reviewed. **S**

## Current medications

- Metformin 1,000 mg oral tablet, one tablet twice daily with meals **S**
- Lisinopril 20 mg oral tablet, one tablet daily **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**
- Donepezil 5 mg oral tablet, one tablet at bedtime **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/78 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 76.6 kg; BMI 23.6 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 126/78; pulse 70; weight 76.6 kg |
| Mental status | Attentive during the disclosure; asks good questions; mood sad but reactive |
| Gait | Steady; Timed Up and Go 9 seconds |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Alzheimer's disease with early onset** (G30.0). Amyloid PET positive: the amnestic mild dementia is due to Alzheimer's disease, beginning before 65. Repetitive head impacts may have added to his difficulty, and traumatic encephalopathy syndrome remains a research diagnosis that cannot be confirmed in life; it would not change his treatment. He is not a candidate for anti-amyloid antibodies because of the microbleeds. Donepezil offered for modest benefit and accepted after a normal ECG. **S**
   - Donepezil 5 mg at bedtime; raise to 10 mg after four to six weeks if tolerated.
   - MoCA and CDR yearly, or sooner with change.
   - Exercise and social activity to continue.
2. **Mild dementia due to Alzheimer's disease** (F02.A0). CDR 1. Getting lost while driving and the CDR put him at high risk at the wheel; after discussion he agreed to stop driving. He agreed to have the handgun taken out of the home. **S**
   - No driving; transport through his care partner and paratransit.
   - Handgun removed from the home.
   - Care partner: Alzheimer's Association 24/7 Helpline, a caregiver class, and an adult day program two days a week for respite.
   - GUIDE dementia care program once he has Medicare.
3. **Type 2 diabetes** (E11.9). A low reading of 68 mg/dL on glipizide with hemoglobin A1c 6.4%: under the ADA Standards for an older adult with cognitive impairment, the goal is under 8.0% and sulfonylureas should be stopped to avoid hypoglycemia. **S**
   - Stop glipizide.
   - Continue metformin; hold it on days he cannot eat or drink.
   - Hemoglobin A1c at about three months.
4. **Bilateral sensorineural hearing loss** (H90.3). Hearing aids recommended by the audiologist. **S**
   - Hearing aid fitting in two weeks.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Cognitive testing (MoCA, MMSE) | At diagnosis, then yearly, or sooner with change | Up to date | MoCA 18 and MMSE 22 at diagnosis; next in a year |
| Survey | Dementia staging (CDR) and function (ADL and IADL) | At diagnosis, then yearly | Up to date | CDR 1 two weeks ago |
| Imaging | Amyloid biomarker confirmation (PET or CSF) | Once, when it will change diagnosis or treatment | Completed today | Amyloid PET positive (about 90 Centiloids), reviewed with him today |
| Medication safety | Anti-amyloid antibody eligibility (lecanemab, donanemab), APOE genotyping and ARIA MRI schedule | At diagnosis of MCI or mild dementia due to Alzheimer's disease | Not indicated | Not a candidate because of six microbleeds; explained to him today |
| Medication safety | Medicine review for anticholinergic and sedating drugs (Beers) | Every visit | Completed today | No anticholinergic or sedating drugs; glipizide stopped for hypoglycemia risk |
| Survey | Behavioral and psychological symptoms (NPI-Q items) | Every visit | Completed today | None; sad at the news without depression |
| Medication safety | Cholinesterase inhibitor: benefit, nausea, diarrhea, dreams, pulse | Each follow-up and each dose change | Completed today | Donepezil 5 mg started after a normal ECG (pulse 70) |
| Self-management | Driving, firearm and home safety | At diagnosis and each follow-up | Completed today | Agreed to stop driving; handgun to be removed from the home; stove shut-off advised |
| Self-management | Care partner support and burden (Zarit, narrative) | At diagnosis, then at least yearly | Completed today | Zarit 18 (mild burden); helpline, caregiver class and adult day program arranged; GUIDE explained for when he has Medicare |
| Self-management | Advance care planning | At diagnosis; revisit yearly and at changes | Due | Booked at the preventive visit in three weeks, while he can take part fully |
| Laboratory | Hemoglobin A1c, goal under 8.0% for an older adult with cognitive impairment, and hypoglycemia review | Every three months after a therapy change; every six months when stable | Up to date | 6.4% at intake; one low reading; glipizide stopped; A1c due in about three months |
| Examination | Blood pressure, goal under 130/80 mmHg | Every visit | Completed today | 126/78 mmHg |
| Laboratory | Potassium and creatinine on lisinopril and metformin | Yearly, and after acute illness or dehydration | Up to date | Normal at intake |
| Examination | Dilated diabetic eye examination | Every one to two years without retinopathy | Referred | Still pending; he now depends on others for transport |
| Self-management | Exercise and social activity | Every visit | Completed today | Walks daily; the foundation gym twice a week |

## Goal progress

- Find the cause of the memory loss and explain it to him in a way he can take in. Outcome by 1984-08-18: Alzheimer's disease confirmed by amyloid PET; disclosed with his care partner present, at his request, with written notes. **S**
- No hypoglycemia, with hemoglobin A1c under 8.0%. In progress; target 1984-10-27. **S**
- Stay safe: no driving and no firearm in the home. Outcome by 1984-08-18: He stopped driving and the handgun was removed from the home. **S**
- Keep his days full and give his care partner regular breaks. In progress; target 1984-10-27. **S**

## Medication changes

- Stopped: Glipizide 5 mg oral tablet, one tablet before breakfast **S**
- Started: Donepezil 5 mg oral tablet, one tablet at bedtime **S**

## Guideline basis

- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024), Alzheimer's Association (Alzheimers Dement 2025;21(1):e14337)
- CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, diabetes type 2 and hypertension monographs (2026), Aether Forge
- Lecanemab: Appropriate Use Recommendations (2023), J Prev Alzheimers Dis 2023;10(3):362-377 (Cummings J et al.)
- Donanemab: Appropriate use recommendations (2025), J Prev Alzheimers Dis 2025;12(5):100150 (Rabinovici GD et al.)
- National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021), Neurology 2021;96(18):848-863
- 13. Older Adults: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1):S277-S296)
- Practice Parameter update: Evaluation and management of driving risk in dementia (2010), American Academy of Neurology (Neurology 2010;74(16):1316-1324)
- Guiding an Improved Dementia Experience (GUIDE) Model (2024), Centers for Medicare & Medicaid Services, Innovation Center

## Follow-up

- Preventive visit with advance care planning in three weeks. Hearing aid fitting in two weeks. Eleven-week review with hemoglobin A1c. Call for low glucose readings, falls, or nausea on donepezil. **S**
- Next scheduled visit 1984-09-08: periodic adult preventive visit. **S**
